Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Beats Expectations By $1.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) released its earnings results on Friday. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13, MarketWatch Earnings reports. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.47% and a return on equity of 18.61%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. During the same period last year, the business earned $10.96 EPS.

Regeneron Pharmaceuticals Trading Down 1.3 %

Shares of REGN stock traded down $12.60 on Friday, hitting $945.18. 752,000 shares of the stock traded hands, compared to its average volume of 503,120. The firm’s 50-day moving average price is $886.91 and its two-hundred day moving average price is $833.97. The company has a debt-to-equity ratio of 0.11, a quick ratio of 4.47 and a current ratio of 5.18. The stock has a market capitalization of $102.98 billion, a PE ratio of 27.20, a PEG ratio of 2.86 and a beta of 0.11. Regeneron Pharmaceuticals has a twelve month low of $684.80 and a twelve month high of $973.99.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total transaction of $82,790.00. Following the transaction, the director now owns 18,547 shares of the company’s stock, valued at approximately $15,355,061.30. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total value of $82,790.00. Following the transaction, the director now owns 18,547 shares of the company’s stock, valued at $15,355,061.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,911 shares of company stock valued at $8,884,428. 8.83% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Equitable Holdings Inc. increased its stake in Regeneron Pharmaceuticals by 1.5% during the first quarter. Equitable Holdings Inc. now owns 967 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 14 shares during the period. Johnson Investment Counsel Inc. increased its stake in Regeneron Pharmaceuticals by 1.4% during the first quarter. Johnson Investment Counsel Inc. now owns 1,090 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 15 shares during the period. IHT Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 3.1% during the second quarter. IHT Wealth Management LLC now owns 561 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 17 shares during the period. Plancorp LLC increased its stake in Regeneron Pharmaceuticals by 0.8% during the first quarter. Plancorp LLC now owns 2,276 shares of the biopharmaceutical company’s stock worth $1,590,000 after purchasing an additional 17 shares during the period. Finally, Orion Portfolio Solutions LLC increased its stake in Regeneron Pharmaceuticals by 2.1% during the first quarter. Orion Portfolio Solutions LLC now owns 962 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 84.15% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Raymond James upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $950.00 target price for the company in a research note on Friday, November 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $1,076.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, January 29th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Truist Financial reissued a “buy” rating and set a $1,045.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, December 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $925.52.

Get Our Latest Report on REGN

Regeneron Pharmaceuticals Company Profile

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.